Cori Clinical raises $4M seed to cut clinical trial delays with AI

Cori Clinical has raised $4 million in seed funding to apply AI to clinical trial design, aiming to reduce delays that extend drug development timelines. The round was led by Breega, with participation from Enzo Ventures, Heartfelt, Together Ventures, and Bynd.

The company’s platform focuses on optimizing trial protocols, a stage where inefficiencies can add significant time to the process. Clinical trials often face bottlenecks due to design complexities, recruitment challenges, or regulatory hurdles. Cori’s approach targets the earliest phase of trial planning, where AI-driven analytics could help sponsors avoid costly revisions later.

The funding arrives as AI adoption in drug development gains momentum, though many applications have focused on discovery or patient recruitment. Cori’s emphasis on trial design positions it in a niche segment, where specialized tools may offer value even as broader AI healthcare plays attract more capital.

Breega’s lead role may reflect European investor interest in AI-driven healthcare solutions, particularly those addressing systemic inefficiencies. The participation of Bynd, a firm with ties to corporate venture arms, suggests potential enterprise adoption by pharmaceutical companies.

What remains to be seen is how Cori’s technology differentiates from existing solutions, or whether its AI can scale beyond early-stage trial design. For now, the seed round provides runway to refine its product and test it with partners. If successful, it could push larger players to consider similar capabilities—whether through integration or acquisition.

Sources: tech.eu